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Abstract
Background: In order to provide reliable tissue material for malignant mesothelioma (MM) studies, we re-evaluated
biopsies and autopsy material from 61 patients with a diagnosis of MM from the period of 1980-2002.
Methods: Basic positive (Calretinin, EMA, Podoplanin, Mesothelin) and negative (CEA, Ber-Ep4)
immunohistochemical (IHC) marker reactions were determined. If needed, more markers were used. Histological
diagnoses were made by three pathologists. Survival data were calculated.
Results: 49 cases (80%) were considered being MM by a high degree of likelihood, five more cases possible MM.
Of the remaining seven cases, three were diagnosed as adenocarcinoma, three as pleomorphic lung carcinoma, in
one peritoneal case a clear entity diagnosis could not be given. One of the possible MM cases and two of the
lung carcinoma cases had this already as primary diagnoses, but were registered as MM.
With a sensitivity of 100%, Calretinin and CEA were the most reliable single markers. The amount of MM cells with
positive immunoreactivity (IR) for Podoplanin and Mesothelin showed most reliable inverse relation to the degree
of atypia.
In the confirmed MM cases, there had been applied either no IHC or between one and 18 markers.
The cases not confirmed by us had either lacked IHC (n = 1), non-specific markers were used (n = 4), IR was
different (n = 1), or specific markers had not shown positive IR in the right part of the tumour cells (n = 3).
46 of the 49 confirmed and three of the not confirmed cases had been diagnosed by us as most likely MM before
IHC was carried out.
Conclusions: In order to use archival tissue material with an earlier MM diagnosis for studies, histopathological
re-evaluation is important. In possible sarcomatous MM cases without any positive IR for positive MM markers,
radiology and clinical picture are essential parts of diagnostics. IHC based on a panel of two positive and two
negative MM markers has to be adapted to the differential diagnostic needs in each single case. New diagnostic
tools and techniques are desirable for cases where IHC and other established methods cannot provide a clear
entity diagnosis, and in order to improve MM treatment.
Background
Modern molecular techniques applied on tissue
specimens have increased the interest in using archival
material for research purposes. The risk of wrong
diagnosis by doing so might be high due to the lack of
immunohistochemical (IHC) evaluation at the time of
diagnosis.
Malignant mesothelioma (MM) is a tumour that
traditionally has been considered being difficult to diag-
nose histologically in a substantial subset of cases. To our
knowledge, the extent of misdiagnosis of MM in archival
material has not been studied systematically earlier, with
the exception of one recent study [1].
MM is a highly aggressive tumour defined as derived
from mesothelial cells [2,3]. It is considered an almost
incurable disease. Its molecular profile indicates that
most of the known genes for radio- and chemoresis-
tance are overexpressed [4,5].
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sarcomatous and mixed types, where the less common
mixed and sarcomatous variants show a poorer survival.
Sometimes a desmoplastic type is added, which may be
diagnosed as either epithelial, mixed or sarcomatous
type [6,7]. For the mixed type MM, International
Mesothelioma Panel (IMP)/World Health Organization
(WHO) require the presence of arbitrarily at least 10%
of either an epithelial or a sarcomatous component [3].
According to recent studies, median survival after diag-
nosis is 4.5 to 17 months, depending on histological
type, tumour stage, performance status and treatment,
and other factors as gender and age [8-11].
In Norway, registered new MM cases have continuously
increased from five cases in the period of 1958-62 to 382
cases in the period of 2003-07. In the last period, 88% of
registered cases were histologically verified. By adding the
cytologically diagnosed cases the rate of morphologically
diagnosed cases reached nearly 100% (97.5% of 360 cases in
the period of 2001-05) [12-14]. However, in its recent guide-
lines the European Respiratory Society (ERS)/European
Society of Thoracic Surgeons (ESTS) Task Force does not
recommend making a MM diagnosis based on cytology
alone because of the high risk of diagnostic error [15].
Before IHC became a part of routine pathology in the
end of the 1980s/beginning of the 1990s, and especially
before more MM-specific positive IHC markers were
introduced a few years later, it could be difficult or even
impossible to differentiate MM from other malignant
tumours, such as primary or metastatic adenocarcino-
mas (AC) in a part of the cases. Around 1995, antibo-
dies against Wilms tumour protein (WT) 1, around
1998, against Calretinin and around 2005, against Podo-
planin/D2-40 were introduced into routine diagnostics
as new positive MM markers [16-22].
T h ei n t r o d u c t i o no fs u c hm o r es p e c i f i cp o s i t i v em a r -
kers, in combination with distinctive negative markers
has significantly improved the possible accuracy of MM
diagnosis. However, there is no reliable single MM IHC
marker. The IMP/WHO and the International Mesothe-
lioma Interest Group (IMIG) recommendations on MM
IHC diagnostics comprise a panel of at least two positive
and two negative antibodies [3,23].
This study aimed primarily at establishing histopatho-
logical diagnoses on archival tissue material from
patients diagnosed as MM, in order to get a reliable
basis for further studies using recent histological and
IHC criteria. Furthermore, we wished to find out how
the availability and choice of IHC markers may have
influenced MM diagnosis.
Methods
The archival material in this study has been used in two
previous studies where verification of the histological MM
diagnoses was mandatory [11,24]. Use of the material was
approved by the Regional Ethical Committee.
Paraffin-embedded tissue material from 73 patients
taken between 1980 and 2002 was received from 19
Norwegian departments of pathology. Primary MM
diagnoses had been given mostly based on tumour biop-
sies, and/or in a few cases on autopsy material. Tissue
specimen volumes varied from a few mm
3 in needle
biopsies to some cm
3 in autopsy material. Clinical and
radiological data were fragmentary, and limited to those
received in written form by the primarily diagnosing
pathologists in the histology requisitions. After having
received additional clinical information, tumour localisa-
tion was adjusted to both pleura and peritoneum in
three cases, and to scrotum in one case, compared with
earlier data [11,24]. From two of the four patients with
MM both in pleura and peritoneum, autopsy material
from both localisations was disposable, from the others
the biopsies were only from one site.
From the paraffin blocks, Hematoxylin-Eosin-Saffron
(HES) stained slides were made. For 61 patients (84%),
the samples showed a sufficient amount of remaining
tumour tissue suitable for diagnosis by the planned IHC
procedure. Preliminary, exclusively HES-based tentative
diagnoses were established. Basic histological parameters
were determined on HES-stained slides. Mitoses were
counted per so-called high-power fields (HPF), consti-
tuted by 40 times of objective and 10 times of ocular
magnification.
After having determined optimal antibody dilution
individually for each marker, by applying established
IHC protocols from routine pathology and in the
remaining cases by testing optimal dilutions, IHC was
performed by the standardised Dako Cytomation proto-
col DAKO REAL™ EnVision™ with peroxidase/diamino-
bencidine and chromogen, rabbit/mouse [25]. The
minimum procedure included four positive (Calretinin,
Epithelial Membrane Antigen (EMA) membranous,
Mesothelin, Podoplanin) and two negative (carcino-
embryonic antigen (CEA), Ber-Ep4) markers, and in a
subset of cases, if considered necessary, additional IHC
markers (each case including, as a minimum, Hector
Battifora Mesothelial Cells (HBME) 1 and Thrombomo-
dulin as positive and CD15 and Sialosyl-TN as negative
markers, before applying Mesothelin and Podoplanin)
and Alcian Blue staining. In order to reach a reliable
MM diagnosis, in five cases of epithelial type MM (No.
30, 39, 62, 74, 75) (12%) and in two cases of mixed MM
(nr. 11 and 25) (25%), this second set of four basic IHC
markers was applied. Reasons for this were too weak
and/or not typical immunoreactivity (IR).
Slides were evaluated in multiple steps defined by the
used basic and additional antibodies, by two pathologists
(E. Larsson, H. Sandeck) independently, finally by a third
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without access to the previous histological diagnoses.
After each step, the diagnosis or eventual markers to add
were determined by consensus. Our MM selection criteria
included the histological MM variants and subtypes
according to the current WHO MM classification and
clearly positive IHC staining in at least a part of the
tumour tissue, or absence of staining by the mentioned
positive and negative markers, respectively [3]. For the
diagnosis of a sarcomatous type or component, we
regarded a predominant spindle cell pattern as indispensa-
ble [26]. A definitive entity diagnosis was only given when
there was a high degree of likelihood for the entity based
on morphology and IHC, with positive IR for at least one
positive MM marker (Table 1).
Cases with negative IR were coded 0 and those with
positive IR were classified into quartiles (H. Sandeck).
Sensitivity (number of MM cases with positive IR
divided by total number of MM cases that underwent
IHC for the marker in question) and specificity (number
of carcinoma reference cases with negative IR divided by
total number of carcinoma reference cases for the
marker in question) were calculated for positive and
negative MM IHC markers.
Survival data were obtained from the Cancer Registry
of Norway. These and the microscopic data were pro-
cessed in the statistical software SPSS, v. 16.0 (Producer:
SPSS Inc., IBM Company, Chicago, USA), with survival
being a dependent variable. Survival dependent on each
single histological and IHC parameter and on a few
Table 1 Immunohistochemical markers used for malignant mesothelioma diagnosis in this study
IHC marker Antigen type Clone Producer Code No. Dilution
Positive markers
Calretinin Calcium-binding protein polyclonal Zymed 18-0211 1: 1,500
EMA HMFG protein E-29 Dako M0613 1: 750
Thrombomodulin endothelial cell transmembrane glycoprotein 1009 Dako M0617 1: 50
HBME-1 mesothelial cell membrane protein HBME-1 Dako M3505 1: 50
Mesothelin cell surface glycoprotein 5B2 Novocastra NCL-L-MESO 1: 10
Podoplanin transmembrane mucoprotein n.s., monoclonal Angiobio 11-003 1: 50
CK5/6 IMF D5/16 B4 Dako M7237 1: 80
CK7 IMF OV-TL12/30 Dako M7018 1: 1,000
CK AE1/AE3 IMF (pan-CK cocktail, subfamilies A and B) AE1 and AE3 Dako N1590 1: 75
CK KL1 IMF (pan-CK cocktail) KL1 Serotec MCA144H 1: 50
Negative markers
monoclonal CEA Gold 1 epitope II-7 Dako M7072 1: 200
polyclonal CEA CEA and CEA-like proteins polyclonal Dako A0115 1: 13,000
Ber-Ep4 transmembrane glycoprotein Ber-Ep4 Dako M 0804 1: 200
CD15 Lewis X carbohydrate antigen C3D-1 Dako M0733 1: 25
Sialyl-TN Sialosyl-Tn1 glycoprotein HB-STn1 Dako M0899 1: 100
TTF-1 nuclear transcription factor 8G7G3/1 Dako M3575 1: 100
Others
CK20 IMF Ks 20.8 Dako M7019 1: 200
CD10 neutral endopeptidase 24.11 SS2/36 Dako M0727 1: 50
CD34 single-chain transmembrane protein QBEnd 10 Dako M7165 1: 100
CD68 glycosylated lysosomal membrane protein KP1 Dako M814 1: 3,000
CD99 MIC2 gene products 12E7 Dako M3601 1: 100
Bcl-2 apoptosis inhibitor 124 Dako M0887 1: 200
SMA microfilaments 1A4 Dako M0851 1: 300
Desmin IMF D33 Dako M0760 1: 100
S-100 Calcium-binding proteins polyclonal Dako Z0311 1: 3,000
HMB-45 part of neuraminidase-sensitive glycoconjugate in melanosomes HMB45 Dako M0634 1: 100
HHF-35 muscle actin HHF 35 Dako M0635 1: 200
MIB1 nuclear protein, proliferation marker Ki-67/MIB-1 Dako M7240 1: 200
Abbreviations:
IMF - intermediate filament; EMA - Epithelial Membrane Antigen; HMFG - Human Milk Fat Globule; HBME - Hector Battifora Mesothelial (Human MesothelialC e l l
Antigen); CK - Cytokeratin; AE - Anti-Epithelial; KL1 - Keratin L1; CD - Cluster of Differentiation; TTF - Thyroid Transcription Factor; Bcl - B-cell lymphoma; SMA -
Smooth Muscle Actin; HMB - Human Melanoma Black; HHF - Human Heart Fibroblasts/myofibroblasts; MIB - Molecular Immunology Borstel; Ki - Kiel
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Kaplan-Meier plots. Parametric linear (Pearson) and
non-parametric (Kendall’s tau-b, Spearman’s rho) bivari-
ate correlations to survival were analysed with regard to
significance. A multivariate linear model was calculated.
Results
Re-classification
Of the 61 evaluable cases, 49 (80%; 40 men, 9 women)
w e r ed i a g n o s e da sM M ,4 0( 8 2 % )a se p i t h e l i a la n d8
(16%) as mixed type. Of the mixed type cases, seven
were localised in pleura, two of them were autopsy cases
that showed secondary spreading via diaphragm into
peritoneum. The remaining case was located in scrotum.
All of the mixed MM types occurred in men. In one
pleural case (No. 7) (2%), typing was undetermined
between epithelial and mixed because of ca. 10% of sar-
comatous component. All four cases of MM affection in
both pleura and peritoneum were observed in men. A
summary of our results is shown in Table 2 [see also
Figure 1, Figure 2, Figure 3, Figure 4, Figure 5, Figure 6].
One earlier diagnosis of epithelial type had to be
changed to mixed type when autopsy material was
included (No. 11) (related to [11,24]). The remaining 12
cases (20%; 10 men, 2 women), represented various
malignancies, where the primary MM diagnosis was
either abolished (n = 7) or set more in doubt (n = 5).
Of the five cases in which MM yet was considered pos-
sible, one was without IHC in primary diagnosis (No. 5);
in the other four cases, the IHC profile was not consid-
ered being sufficient for a MM diagnosis (No. 57, 32,
63, 12). In four of these cases, sarcomatous MM and
not furthermore specified sar c o m aw e r ed i f f e r e n t i a l
diagnoses, while there were no sufficient indications for
sarcomatous carcinoma (No. 5, 57, 32, 63) (Tables 3, 4)
[see Figure 7, Figure 8, Figure 9, Figure 10, Figure 11
and Figure 12].
In one of the possible MM cases (No. 5) and two of the
lung carcinoma cases (No. 3, 6) primary histological diag-
noses were in accordance to our diagnoses, but had been
registered as MM in the Cancer Registry. This was done
apparently by clinicians who did not accept the histological
diagnoses (No. 3, 6), or the likelihood consideration
expressed in one of them (No. 5). Thus, in a stronger sense,
only nine previous MM diagnoses (9/61, 15%), namely his-
tological ones, were not confirmed by us. Four of them
Table 2 Classification of cases
Female Male Total
Total number of evaluable cases 11 50 61
Validated MM 9 40 49
(80%)
Epithelial/mixed/between epithelial and
mixed type
9/0/0 31/8/
1
40/8/1
Pleura/mediastinum/pericardium
- Epithelial type 6/1/0 24/0/
1
30/1/1
- Mixed type 0/0/0 5/0/0 5/0/0
- Between epithelial and mixed type 0/0/0 1/0/0 1/0/0
Peritoneum/pleura and peritoneum/scrotum
- Epithelial type 2/0/- 3/2/1 5/2/1
- Mixed type 0/0/- 0/2/1 0/2/1
Others 2 10 12
(20%)
Adenocarcinoma, lung 0 2 2
Adenocarcinoma, peritoneum 1 0 1
Pleomorphic carcinoma 0 3 3
No definitive entity diagnosis,
amongst them MM as one differential
diagnosis
1
0
5
5
6
5
Figure 1 Calretinin. Predominantly nuclear, less cytoplasmatic
staining. Epithelial type MM, pleura. Biopsy, 400×. Pat. no. 1.
Figure 2 Calretinin. Predominantly nuclear staining. Mixed type
MM, pleura. Autopsy material, 400×. Pat. no. 69.
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mined with possible MM in four of them (Table 4).
11 of the 12 mentioned, with respect to MM not con-
firmed cases had been diagnosed primarily in university
departments of pathology. In eight of the 49 confirmed
cases and in one of the not confirmed cases no university
department was ever involved in primary diagnosis. Institu-
tional affiliation of primary diagnosis is shown in Table 5.
In all but one (No. 9, pleomorphic carcinoma of the
lung) of the eight cases with diagnoses based on autopsy
material, primary MM diagnoses were confirmed. In six
cases the basis marker set of Calretinin, EMA, CEA and
Ber-Ep4 was sufficient for diagnosis, there were five
epithelial MM and one mixed MM. In one case, more
IHC markers were considered being necessary, here our
diagnosis was mixed type MM.
Sensitivity and specificity of IHC markers
Based on the five pulmonary carcinoma cases, specifi-
city was lower than sensitivity for Podoplanin, EMA
and monoclonal CEA, but 100% for Calretinin and
Mesothelin. Concerning sensitivity, the most reliable
single markers amongst the six markers were Calreti-
nin and CEA. However, in two of 49 MM cases Calre-
tinin showed positive IR only in a few tumour cells
(Table 6). No difference in MM IR for monoclonal and
polyclonal CEA was detected, although inflammatory
cells gave a positive IR for polyclonal, and not for
monoclonal CEA.
Marker expression in relation to grade of atypia
Two of 49 MM cases (4%) showed the lowest degree of
cytological atypia in the material, grade 1 and 1.5, and
three of them (6%) high atypia, grade 3. The expression
Figure 4 Epithelial membrane antigen. Partially cytoplasmatic,
predominantly membranous staining. Mixed type MM, epithelial
component, pleura. Biopsy, 400×. Pat. no. 33.
Figure 5 Mesothelin. Membranous staining. Epithelial type MM,
pleura. Biopsy, 400×. Pat. no. 1.
Figure 6 Podoplanin. Microvilli staining. Epithelial type MM,
peritoneum. Biopsy, 400×. Pat. no. 52.
Figure 3 Epithelial membrane antigen. Various intensities of
staining from negative to strongly positive, predominantly
membranous. Epithelial type MM, pleura. Biopsy. 400×. Pat. no. 1.
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in all cases low compared to the grade 1 till 2 cases.
In five cases there were a few MM cells, near 0%, with
positive IR for Ber-Ep4, in four cases some more, but
less than 25% of MM cells. IR for CEA was negative in
all cases (not shown). Of the four positive markers, Cal-
retinin and EMA were most expressed even in poorly
differentiated MM (Table 7).
No obvious differences in IHC staining intensity and
distribution were seen between biopsy and autopsy
Table 3 Diagnostic certainty dependent on localisation of primary tumour
Localisation Confirmed MM Possible MM No MM
Fem. Male Total Fem. Male Total Fem. Male Total
Lung/pleura 6 30 36 0 5 5 0 5 5
Mediastinum (n.s.) 1 0 1 0 0 0 0 0 0
Pericardium 0 1 1 0 0 0 0 0 0
Pleura and peritoneum 0 4 4 0 0 0 0 0 0
Peritoneum 2 3 5 0 0 0 2 0 2
Scrotum - 2 2 - 0 0 - 0 0
Sum 9 40 49 0 5 5 2 5 7
n.s.: localisation not furthermore specified
Data are based on primarily registered MM.
Table 4 Possible causes of diagnostic discordance related to time of diagnosis
Possible causes Pat.
ID
Sex Year Our tentative HES
diagnosis
Primarily registered MM diagnoses changed to:
Right histological diagnosis
(without use of IHC) not
accepted by clinicians,
registered as MM in Cancer
Registry
5
3
6
M
M
M
1986
1988
1988
MM/LMS
MM
MM/C
undetermined: sarcoma, lung or pleura/sarcomatous MM,
pleura
AC, lung
pleomorphic carcinoma, lung
No IHC 9 M 1991 MM/C pleomorphic carcinoma, lung
Use of non-specific markers 57
72
31
49
M
M
M
F
1989
1996
1998
1998
MM
MM/C
Mal. tu.
S/LMS?
undetermined: sarcoma, lung or pleura/sarcomatous MM,
pleura
AC, lung
pleomorphic carcinoma, lung
undetermined: sarcoma/sarcomatoid carcinoma,
peritoneum
Differences in IR
1 58 F 1999 MM/C AC, peritoneum
Not appropriate conclusions
2 32
63
12
M
M
M
1999
2001
2002
MM
Ben./MM?
Mal. Mel.
undetermined: sarcoma, lung or pleura/sarcomatous MM,
pleura
undetermined: sarcoma, lung or pleura/sarcomatous MM,
pleura
undetermined: AC, lung > MM, pleura
1 between the primary laboratory and our laboratory, in addition misinterpretation of IR of another marker (one case: 58; Ber-Ep4 from negative IR in primary
diagnosis to positive IR in our diagnosis, EMA positive IR only in cytoplasm)
2 based on a few relevant MM markers that showed no typical MM pattern
AC - adenocarcinoma; C - carcinoma; S - sarcoma; LMS - leiomyosarcoma; Mal. - malignant; Tu. - tumor; Ben. - benign; Mel. - melanoma
None of these cases had been referred to a second opinion.
All cases were registered as MM, partially despite of histological diagnoses.
Primary histological diagnoses were:
Pat. 5: Malignant mesenchymal tumour, MM possible, no epithelial component seen
Pat. 3: Poorly differentiated carcinoma most likely, MM less likely
Pat. 6: Carcinoma most likely
Pat. 9: MM
Pat. 57: MM likely
Pat. 72: MM likely
Pat. 31: MM possible
Pat. 49: MM
Pat. 58: MM
Pat. 32: MM most likely
Pat. 63: MM, sarcomatous type
Pat. 12: MM
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in the latter one, or related to the age of the tissue
material (not shown). However, there were only four
cases with both biopsy and autopsy material, with par-
tially insufficient amount of the former one. A systema-
tic comparison of marker expression in these cases as in
[32] was not performed.
Use of IHC in primary diagnosis in the confirmed MM
cases
In at least 26 cases (53%) between one and 18 IHC mar-
kers had been applied (Table 8). In all but one of the
confirmed cases, the positive marker combination Calre-
tinin and EMA could have been replaced by the combi-
nation Podoplanin and Mesothelin, leading to the same
diagnosis. In one case (autopsy, No. 70) which showed
only a few nuclei with positive IR for Calretinin and
positive membranous IR for EMA in less than 25% of
cells, the combination Podoplanin and Mesothelin, with
IR in two and three quartiles of tumour cells, respec-
tively, would have been a better option. However, in a
case of MM of tunica vaginalis testis (biopsy, No. 25)
with only a few cells showing the same kind of IR for
Calretinin and EMA, IR for Podoplanin and Mesothelin
were completely negative.
Use of IHC in primary diagnosis in the not confirmed MM
cases
Four of the 12 not confirmed cases from between 1986
and 1991 lacked IHC. In four cases from between 1989
and 1998, non-specific IHC markers were applied. One
case from 1999 (No. 58) showed different IR for one
crucial negative MM marker, Ber-Ep4, which was
described as negative in primary diagnosis, but which
showed positive IR in our IHC staining. The positive
Figure 7 Adenocarcinoma, lung. TTF-1. Biopsy, 200×. Pat. no. 3.
Figure 8 Pleomorphic giant cell carcinoma, lung. TTF-1. Biopsy,
200×. Pat. no. 9.
Figure 9 Possible sarcomatous MM, chest wall.P o s i t i v eI Rf o r
Calretinin in some spindle cells. Biopsy, 200×. Pat. no. 57.
Figure 10 Possible epithelial MM, lung/pleura.M e m b r a n o u s
positive IR for Podoplanin in some cells. Biopsy, 400×. Pat. no. 12.
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In the remaining three cases from between 1999 and
2002 which all are of undetermined entity, combinations
of relevant IHC markers including Calretinin, EMA and
Ber-Ep4 were used, but Calretinin showed negative IR
and EMA positive IR in cytoplasm. In five of the six
undetermined cases, MM is still one of the differential
diagnoses (Tables 2, 4) [see Additional file 1].
Tentative diagnosis without IHC
In 46 of the 49 cases confirmed by us (94%) we
previously also had diagnosed MM as most likely based
on HES slides only. In the remaining three cases, MM
was a differential diagnosis together with carcinoma. In
eight of the 12 not confirmed cases (67%), MM was one
of our tentative differential diagnoses. In three of
these cases (25%), MM was our only tentative diagnosis.
Two of the latter cases remained undetermined, one
case showed most likely pulmonary AC after IHC
(Table 4).
Survival
Overall median survival was 12.5 months, with almost
no difference between men and women (12.2 and 12.5
months, respectively). Pleural MM survival ranged from
0 to 44 months, with a median of 12.5 months. Mediast-
inal, pericardial and scrotal MM (1/1/2 cases) survival
was 2.5, 4, 6 and 10 months, respectively. The longest
median survival, 51.8 months, was observed in perito-
neal MM, with a minimum of 5.5 months in men and
31.5 months in women.
Survival was in the statistic median and mean poorer
when IHC Mesothelin expression was reduced, this was
also true for Calretinin in nuclei and even more for
Podoplanin, which was the only IHC marker showing
significant bivariate correlation [11]. Mixed type, pre-
sence of spindle cells, high cellular atypia, more than
one mitosis per 10 HPF, presence of atypical mitoses,
necrosis, presence of regional lymph node and/or distant
metastases and elevated age at diagnosis were correlated
with poorer survival. Peritoneal MM was correlated with
longer survival than MM in all other localisations. All of
these parameters, except the number of atypical mitoses,
showed significant bivariate correlation with survival,
too (Table 9).
Multivariate linear analysis revealed a model to which
only localisation in peritoneum, cellular atypia and
necrosis contributed significantly, namely at <0.05 levels
(at 0.001 level, 0.031 and 0.032, respectively), not the
other parameters that had shown significant bivariate
correlations with survival (0.2 till 0.9 levels in multivari-
ate analysis).
Women were only represented in the primary diagno-
sis age groups of 45 till 59 years, men in all age groups
from 45 till 79 years. There was a tendency of longer
survival in men then in women in the age groups of 45-
54 years. No relevant differences in survival could be
observed between men and women, when results were
stratified according to localisation in pleura or perito-
neum. All four cases of MM affection in both pleura
and peritoneum were observed in men. Concerning
epithelial type MM, no survival difference was seen
between men and women, mixed type MM was only
observed in men.
Survival in lung AC was 1.5 and 7.5 months, in pleo-
morphic lung carcinoma 1; 3.5 and 13 months, in possi-
ble peritoneal sarcoma/sarcomatoid carcinoma 2
months, in possible pulmonary/pleural sarcoma/sarco-
matous MM (No. 5, 57, 32) 3, 1 and 1 months, in possi-
ble pulmonary AC/pleural MM 2 months and in
peritoneal AC at least 100 months (related to Table 4).
Figure 11 Possible sarcoma, pleura/lung. Positive IR for
Podoplanin nearly only in lymphatic endothelium. Biopsy, 200×. Pat.
no. 5.
Figure 12 Possible sarcoma, pleura/lung. CD99. Biopsy, 400×. Pat.
no. 32.
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In this study, we re-evaluated a Norwegian tissue mate-
rial with an earlier diagnosis of MM which was regarded
as potentially suitable to further molecular studies aim-
ing at a deeper understanding of MM biology [4,11,24].
All patients were donors to the Norwegian Janus
serum bank, as the only applied selection criterion of
the MM material [33].
Our material is not representative concerning MM
type distribution, as there have been diagnosed more
mixed and sarcomatous types in larger newer studies
(Roberts et al. 2001: 73% epithelial/11% mixed/10% sar-
comatous/6% desmoplastic; Borasio et al. 2008: 67%
epithelial/23% mixed/10% sarcomatous), so far as one
supposes that similar diagnostic criteria were applied,
which is not necessarily the case [32,9]. However, when
including the four cases of possible sarcomatous type in
our study, proportions would be more similar (n = 40/
8/4; 77%/15%/8%). MM organ distribution seems to
reflect the overall incidence [12].
Due to scarce material, some relevant antibodies as
WT-1, h-Caldesmon, and others, as well as specific his-
tochemical reactions on glycoproteins and hyaluronic
acid could not be applied, despite of their diagnostic
value [34-36]. More extensive diagnostics including
genetic testing, fluorescence in situ hybridisation (FISH)
Table 5 Institutions in which primary histopathological diagnostics were performed
Institution where primary diagnosis was determined (n = 61)
Non-university dept. University dept.
Original diagnostic unit 19 42
Consultation with another, university department 8 5
Re-evaluation in another,
university department
21
Primary histological diagnosis confirmed 18 (95%) 34 (81%)
Primary histological diagnosis not confirmed 1 (5%) 8 (19%)
Table 6 Sensitivity and specificity, confirmed MM cases
Marker Sensitivity, MM Specificity, against carcinoma
Positive MM markers positive
IR, number
positive
IR, %
literature
data, %
negative IR,
number %
negative
IR, %
literature
data, %
Calretinin, nucleus 49/49 100 82
1
96.4
2
5/5 100 85
1;2
EMA, cell membrane 43/49 87.8 84
3 3/5 60 56
3
Podoplanin, cell membrane 44/46 95.6 86
4 2/3 66.7 100
4
Mesothelin, cell membrane 44/48 91.7 100
5 4/4 100 61
5
Thrombomodulin, cell membrane 7/7 100 61
1 2/5 40 80
1
HBME-1, cell membrane or cytoplasm (4+2)/8 75 85
1 (2-1)/5 20 43
1
CK5/6 3/3 100 83
1 3/5 60 85
1
Negative MM markers negative IR, number negative IR, % positive IR, number positive IR, %
CEA, monoclonal 49/49 100 81
1 1/5 20 97
1
Ber-Ep4 40/49 81.6 80
1 3/5 60 90
1
CD15 7/7 100 84.9
6 1/5 20 81
6
Sialosyl-TN 6/7 85.7 76.5
6 1/5 20 81
6
TTF-1 3/3 100 72
1 5/5 100 100
1
Specificity, own results: against AC and pulmonary pleomorphic carcinoma.
Comparison to some selected data from literature.
1 King et al. 2006, meta-analysis of literature data, MM with epithelioid areas against pulmonary AC [27].
2 Takeshima et al. 2009: sensitivity epithelial/mixed MM 96.4%/90% [1]. Yaziji et al. 2006: sensitivity 95%, specificity against AC 87%, both with 10% positive cutoff
[28].
1, 2 Calretinin IR not specified.
3 Wick et al. 1990, related to epithelial MM and pulmonary AC [29].
4 Ordóñez 2005, related to epithelial MM and AC [21].
5 Ordóñez 2003a, related to epithelial MM and pulmonary AC [30].
6 Brockstedt et al. 2000, related to epithelial/mixed MM and AC [31].
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Page 9 of 15and electron microscopy (EM) in order to possibly reach
a final entity diagnosis in the unclear cases, were not
carried out, since this was not a concern in this study
where the main point was to exclude all insecure and
non-MM cases by a high degree of likelihood
[37,38,23,39].
Our choice of Calretinin, EMA, CEA and Ber-Ep4 was
determined by their diagnostic value, as recently estab-
lished by Brockstedt et al. who singled out CEA and Cal-
retinin as the most informative markers in differential
diagnosis between MM and AC [31]. Their next most
valuable markers were CD15 and EMA, while Ber-Ep4
was fifth. The reason to choose Ber-Ep4 instead of CD15
as one basic negative marker was to test whether Ber-Ep4
really could replace CD15 in this constellation, as it
according to our knowledge apparently has been used
much more. However, direct comparison was only possi-
ble in seven cases where also IHC on markers no. 5-8
(HBME-1, Thrombomodulin, CD15 and Sialosyl-TN)
was performed. As there was partial positive IR for Ber-
Ep4 in two verified MM cases, but negative IR for CD15
in all of the seven verified cases, we too experienced that
CD15 was a more reliable marker than Ber-Ep4. In four
of the seven cases (no. 11, 25, 39, 62), CK5/6 and TTF-1
were considered necessary for confirming the diagnosis.
Mesothelin was chosen in order to compare IR on MM
tissue with serum levels and to evaluate it as an IHC mar-
ker, Podoplanin for the latter reason [4,11,30,40,20,21].
Table 7 Histological grading of atypia and immune reaction for main MM markers
Grade of atypia
(n = 49)
Cases
(n)
Percent
(%)
Calretinin, nucleus
(n = 49)
Epithelial membrane antigen,
cell membrane
(n = 49)
Podoplanin
(n = 47)
Mesothelin
(n = 48)
Ber-Ep4
(n = 49)
10 0 - - - - -
1.5 2 4 4
4
1
3
4
3
4
4
0
0
2 25 51 2.84
(1...4)
2.00
(0...4)
2.65
(1...4)
3.46
(0...4)
.08
(0...1)
2.5 19 39 2.26
(near 0...4)
2.16
(near 0...4)
1.74
(0...4)
3.11
(0...4)
.11
(0...1)
33 6 2
3
1; 1
2
2
2; 1
1
1
1
2
1
1
0
0
0
Number of MM cells with positive IR, semiquantitatively on a 0...4 scale (steps of 25%). For grades 2 and 2.5, average values and overall minimum-maximum
ranges are indicated. IR for CEA was negative in all of the cases.
Table 8 Application of IHC in primary diagnosis in confirmed cases (some patterns, partially overlapping cases)
Year Confirmed
cases
IHC/markers in primary diagnostics
1980-
2002
49 (100%)
19 (39%) No IHC performed
4 (8%) No information available about eventual IHC use
26 (53%) IHC, 1 till 18 markers
No specific positive MM markers
1988-
1999
7 (14%) CEA, Vimentin and Pan-Cytokeratin
Broad spectrum of non-specific markers
1996,
1997
2 (4%) 15/18 markers, 1
st one incl. positive marker HBME-1, otherwise no specific positive MM markers
Positive MM markers
1998-
2002
8 (16%) Calretinin, in all but one (1998) of cases combined with other markers, two cases with another positive marker -
Thrombomodulin and HBME-1, respectively (n = 1-7)
Negative MM markers
1988-
2002
17 (35%) CEA, in all but one (1990) of cases combined with other markers (n = 1-18)
1996,
2002
2 (4%) CD15, combined with, amongst other markers, CEA and Ber-Ep4 (n = 15, 7)
1996-
2002
10 (20%) Ber-Ep4, combined with other markers (n = 4-15)
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Page 10 of 15Table 9 Survival-related single factors, tendencies of correlation
Factor Relation to survival,
clear tendency
Significant (only) in bivariate correlation with
survival (two-tailed), level
IHC markers, semiquantitatively, when increasing number
of cells with positive IR:
Calretinin, nucleus ↑ -
Calretinin, cytoplasm ↔ -
EMA, cell membrane ↔ -
EMA, cytoplasm ↔ -
Podoplanin, cell membrane ↑ 0.001
Mesothelin, cell membrane if 0-50%: ↓
51-100%: ↑
-
Ber-Ep4, general if 1-25%: (↓)-
Histological type
Epithelial ↑ 0.05 (non-parametric)
Mixed ↓ 0.01 (non-parametric)
Histological markers
a) when increasing:
Degree of cellular atypia ↓ 0.001
Spindle cells, semiquantitatively if 0: ↑; otherwise: ↓ 0.001 (non-parametric)
Number of mitoses (10 HPF) if 0 or 1: ↑; otherwise:↓ 0.05 (Spearman’s rho)
Number of atypical mitoses (10 HPF) if 0: ↑; otherwise: ↓ -
Necrosis ↓ 0.01
Mucus, cytoplasm, number of cells if high: (↓)-
Mucus, extracellular, number of cells ↔ -
Accompanying inflammation, intensity ↔ -
Accompanying inflammation, focality ↔ -
b) if present:
MM spreading, perineural (↔)-
MM spreading, intralymphangic (↔)-
MM spreading, intralymphangic and venoles (↓)-
No/no evident MM spreading ↑ -
Accompanying inflammation, active (↔)-
Accompanying inflammation, non-active ↔ -
Localisation of primary tumour
Pleura ↓ -
Peritoneum ↑ 0.01 (parametric)
0.05 (non-parametric)
Pleura and peritoneum (↓)-
Mediastinum, not specified (↓)-
Pericardium (↓)-
Scrotum (↓)-
Metastasis 0.05 (non-parametric)
yes ↓
no/not known ↑
Sex -
Female ↔ -
Male ↔ -
Age at time of diagnosis, when increasing: ↓ 0.01
In parentheses: very few cases
Survival is given per April 21, 2008.
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Page 11 of 15WHO/IMP demand a minimum of 10% sarcomatous
cells to define a mixed MM. In order to reduce MM
typing problems, it has been proposed that at least 30-
40% of a sarcomatous component should be present to
call it a mixed type [41]. This would also be appropriate
in order to avoid taking sarcoma-like stromal reactions
as true sarcomatous MM components. However, in
small biopsies, even such a component ratio may hap-
pen to be not representative at all. Which cytological
and histological patterns are considered to represent a
sarcomatous MM component or type is also varying
[26,42]. Such variations in opinions, approaches and
definitions may cause significant differences in the MM
type frequencies making it difficult or impossible to
compare different studies.
We detected a 15% discrepancy of former histological
MM diagnosis. This could be explained by either 1)
lack of IHC (n = 1), 2) use of non-specific IHC markers
(n = 4), 3) differences in IR (n = 1) or 4) not appropriate
conclusions based on appropriate markers (n = 3) influen-
cing the primary diagnosis.
The case of the first group was from the period before
1998 when no specific IHC markers were available for
actual differential diagnostics in routine pathology.
Today it would be quite uncommon not to use IHC at
all in MM diagnostics, at least in industrialized Western
countries. At the same time, this illustrates the problems
that may occur in countries with a less developed health
care system where IHC might not be affordable.
As to the non-specific markers used in the second
group that covers a period until 1998, this was due to
the lack of more specific markers.
Differences in IR as in the third group and not appro-
priate conclusions as in the fourth group may occur also
today. The former may be reduced by the use of stan-
dardized equipment and workflow in IHC laboratories,
e.g., by IHC staining machines.
In two cases where there had been used non-specific
markers in primary IHC (No. 31, 72), the later (1999)
introduced marker TTF-1 was crucial to establish the
pulmonary carcinoma diagnosis. This also happened in
three of the cases that had lacked IHC (No. 3, 6, 9)
(table 4) [43].
Sarcoma, not further specified, was a differential diag-
nosis in five of the six cases with undetermined re-eva-
luation diagnosis, together with sarcomatous MM of
pleura/lung in four of them. This reflects the potential
diagnostic difficulty in a part of the sarcomatous lesions
of pleura and lung even when IHC is available. In the
one CK-negative (no. 32) and in the four CK-positive
(no. 5, 49, 57, 63) spindle cell tumour cases, Compara-
tive Genomic Hybridisation (CGH) might have allowed
distinguishing between sarcomatous MM and other
entities [37].
The high percentage of cases in which university
departments were involved amongst the cases not con-
firmed by us (8/9, 89%, with respect to histology) may
be partially due to the generally high rate of MM diag-
noses in which a university department was involved
(52/61, 85%). Amongst these cases, there were no con-
sultation cases sent from non-university departments.
Apparently, difficult cases were sent from non-university
departments to university departments for a second opi-
nion, or primary diagnosis. However, in none of the not
confirmed cases, a second opinion was asked for.
Whereas there does not seem to exist poorly differen-
tiated epithelial type MM without any expression of one
or more of such positive markers, as, e.g., Calretinin,
WT-1, Mesothelin or Podoplanin, the complete absence
of IR for such markers is allowed for the sarcomatous
type by the above mentioned definition, as far as there
is a positive IR for broad-spectrum cytokeratins. This
would indeed mean that, with increasing dedifferentia-
tion, specific mesothelial markers disappear, while cyto-
keratins are preserved even in poorly differentiated
sarcomatous MM. However, in cases with completely
negative IR for mesothelial markers, there would not be
any sufficient histological evidence for the presence of
MM. The clinical and radiological picture would then
play a major role in tentative diagnosis.
In a study by Blobel et al., all forms of MM expressed
CK 8 and 18, and most of them CK 7 and 19, the same
CK profile as in AC [44]. In addition, CK 5 was
expressed in all epithelial and most of the mixed types.
CK 4, 6, 14 and 17 were also present in variable
amounts (see also [45]). The authors concluded that
MM has to be defined as a variant of carcinoma. Histo-
logically, this is indeed a reasonable conclusion even
from today’s point of view [46]. Sarcomatous MM could
then be regarded as mesothelial sarcomatoid carcinoma.
On the other hand, several sarcomas also express
cytokeratins.
In our material, 19 MM diagnoses (39%) from the
whole period (1980-2002) which were established with-
out any use of IHC could be confirmed by us. All of
them were also tentatively diagnosed by us as most
likely MM in HES only slides. Apparently, the micro-
scopic pictures in these cases were sufficient in order to
recognize epithelial or mixed type MM. Related to our
final diagnoses, in about 94% of the cases of epithelial
MM, our preliminary, tentative HES-based entity diag-
noses were correct. There would remain about 6% of
diagnostic failure regarding the epithelial subtype alone.
Most often this would concern the differential diagnosis
between MM and AC, which may have therapeutic
implications. In the differential diagnosis of sarcomatoid
lesions, without IHC, there would be a much higher
error rate when the pathological diagnosis is based only
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Page 12 of 15on HE or HES stained slides. This underlines the value
of IHC in MM diagnosis, especially if there is any doubt
concerning the HES picture.
Before more specific MM IHC markers were intro-
duced, in the confirmed MM cases, marker combina-
tions consisting of CEA and Pan-cytokeratin or
Vimentin were applied. Here, negative IR on CEA and
the morphological picture seem to have been crucial for
the MM diagnosis, since there may be positive IR of
both Pan-cytokeratin and Vimentin in carcinomas and
sarcomas. Specific positive MM markers were not avail-
able until approximately 1998 when Calretinin was
introduced in Norway.
All of our confirmed cases showed at least focally
positive IR for Calretinin. However, there were no cases
amongst the not confirmed cases in which missing Cal-
retinin IR would have been the only exclusion criterion
[see Additional file 1].
A basic IHC marker combination of two positive (e.g.,
Calretinin, EMA membranous) and two negative (Ber-
Ep4, CEA) markers was well applicable to distinguish
most of epithelial MM from other differential diagnostic
possibilities. When it is necessary to distinguish MM
from pulmonary AC, and when a synovial sarcoma can
be ruled out, positive IR for TTF-1 would be useful for a
pulmonary carcinoma diagnosis. With the exception of
EMA, all of the mentioned markers are among the
mesothelial and epithelial markers focused on by the
WHO panel [3]. Meanwhile, positive membranous IR for
EMA scored high as a positive MM, or mesothelial mar-
ker in the study of Brockstedt et al. that is based on a
large MM material, and it is also mentioned as usually
negative in benign mesothelial proliferations in the recent
IMIG recommendations [31,23]. EMA is also a recom-
mended marker in the recent ERS/ESTS guidelines [15].
Based on our results, only Calretinin and CEA showed
100% sensitivity (Table 6). In two cases, only a few MM
cells showed positive nuclear IR for Calretinin. One of
them (no. 25) was a mixed MM of tunica vaginalis tes-
tis. In a study of Winstanley et al. on 20 tunica vaginalis
testis cases, all of them showed negative IR for CEA and
positive IR for Calretinin, but only 16 (80%) nuclear IR
for Calretinin [47]. Our second case (no. 75) was an
epithelial MM of pleura that also showed only a few
cells with positive membranous IR for EMA.
Because of the predominating purpose of re-evalua-
tion, the used tissue material was not set up against a
material of non-MM tumours relevant in differential
diagnosis. Thus, our results on specificity of MM IHC
markers cannot be generalized, although the results do
reflect the historical development of MM IHC
diagnostics.
For epithelial MM, IMP and IMIG recommend a
combination of at least two positive and two negative
markers, and a broad spectrum CK mix. They point out
that the preferred markers depend on the experience of
the laboratory, and that more mesothelial, epithelial,
vascular, and malignant melanoma markers can become
necessary if the results are not conclusive [6,23]. In our
study, in the first IHC step, we followed these recom-
mendations, except for the broad spectrum CK antibo-
dies. However, we used three broad spectrum CK
antibodies (AE1, AE3, KL1) together with other markers
in some cases of possible sarcomatous MM where nega-
tive IR on these antibodies would indicate that the
tumour was not a MM. For a diagnosis of epithelial and
mixed MM, more than two positive and negative mar-
kers were considered being necessary in 12% and 25%,
respectively.
Concerning the choice of IHC markers, Marchevsky
and Wick point out the substantial value that odds rate
calculations, systematic reviews and meta-analysis may
have for the development of evidence-based guidelines
for MM diagnosis [48]. This is even true if there are
several possible applicable “optimal” marker combina-
tions, dependant on the experience of the laboratory
and the specific case.
A recent study on accuracy of pathological MM diag-
nosis based on a more than 5-fold larger Japanese mate-
rial (382/73) set up as interdisciplinary re-evaluation
shows with 15.8% (47/298) of all cases diagnosed by
IHC a similar scale of diagnoses classified as “definitively
not/unlikely” MM, compared with 11.5% (7/61) in our
study [1]. The authors defined 80.5% (240/298) of the
IHC cases as “probable/definite” MM, while the corre-
sponding amount in our study was virtually the same,
80.3% (49/61). However, in the Japanese study, even
cytological material and not furthermore processed his-
tological slides were included; IHC was only performed
in 80.6% (308/382) of the cases. As in our study, diag-
nostic accuracy was lower in sarcomatoid lesions. While
there was no agreement in diagnoses in as much as
22.4% of all female pleural and 72.2% of all female peri-
toneal cases, the respective numbers in our study are 0%
(0/6) and 50% (2/4).
Detailed data on exposition to asbestos or other possi-
ble MM risk factors were not available to us. By using
census data from 1970 where occupations had been
classified into having high, moderate or little/no asbes-
tos exposure and expanding them to the 1960 and 1980
censuses, we have earlier made estimations on the possi-
ble asbestos exposure of nearly the same patient group
(n = 47, two patients less than in the current study).
Occupational asbestos exposure was likely in 12
patients, all men. However, these data could not be vali-
dated [11].
Survival analysis revealed no surprising data in respect
of recent oncological knowledge on MM or malignant
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Page 13 of 15tumours in general. The presence of atypical mitoses
alone, irrespective of the number of mitoses, could pos-
sibly be an independent negative prognostic factor, but
this has to be verified or falsified on a larger material.
Any sex preponderance in MM survival could not be
seen in our material. The results of multivariate linear
analysis may not be representative because of the too
low number of cases for this purpose.
Conclusions
Our results underline the need of histopathological
re-evaluation of tissue biopsies with an earlier diagno-
sis of MM, especially those given before the introduc-
t i o no fa tl e a s to n eo ft h em o r es p e c i f i cp o s i t i v eM M
markers that showed a good diagnostic reliability in
our cases. In our opinion, a reliable IHC-based defini-
tion of the sarcomatous MM type has been absent for
cases with negative IR for mesothelium-specific mar-
kers. We have considered such cases not being suffi-
cient for a definitive pathological MM diagnosis, but if
clinical and radiological findings support a MM diag-
nosis in such a setting, nevertheless, a MM diagnosis
may be established. Differential diagnoses in our mate-
rial were adenocarcinoma, pleomorphic and sarcoma-
toid carcinoma and sarcoma. The WHO/IMP and
IMIG recommendations of at least two positive and
two negative IHC markers can be affirmed by our
study, as far as sensitivity is concerned. The marker
choice has to be adapted to the specific differential
diagnostic needs in each single case. In difficult cases,
i tm a yb eu s e f u lt or e f e rt oas e c o n do p i n i o n .
In six cases, despite of relatively extensive IHC appli-
cation, we were not able to give a clear-cut entity diag-
nosis, which may highlight the need of novel diagnostic
tools as biomarkers and other molecular analyses, as
well as new criteria. Such new tools will also be needed
for the more personalized approaches for cancer treat-
ment in the future.
Additional material
Additional file 1: Comparison of primary and re-evaluation IHC/HC
in the 12 cases where MM diagnosis was not confirmed,
chronologically.
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